Start with the clinical scope, not the bottom line
A total price is only meaningful once you know what clinical decision it is pricing. Targeted cancer treatment acts on particular molecular features, and biomarker findings can help clinicians assess potential treatment options. That means the same drug name can sit inside very different plans depending on which biomarker result the treating team is using, what earlier treatments the patient has already had, and what the hospital considers the next appropriate step.
So the first comparison is not hospital A versus hospital B. It is whether both quotes describe the same clinical question. If one hospital is quoting a first-line regimen and another is quoting a later-line option after previous drugs, the totals are not alternatives to each other. They are answers to different questions, and comparing them directly will mislead you.
Before you ask for any figure, write one short paragraph describing the patient's situation: the cancer type, the biomarker or molecular finding already documented, the drugs already received, and the specific decision you need help with. Send that same paragraph to every hospital you approach. It forces each quote to sit on the same foundation, and it makes gaps visible when replies come back.
Ask what the quote assumes about the drug itself
The drug line is where quotes diverge most, and not only because of price. Hospitals may be quoting different products, different dose calculations, different cycle lengths, or a regimen that combines a targeted agent with other treatment. A quote that names only a drug class, or only a brand, is not yet specific enough to compare.
Ask each hospital to state, in writing, the exact medicine name, the dose basis, the number of cycles or the duration the figure covers, and whether the quoted amount is for the medicine alone or for administration as well. If the reply uses a general term, ask for the specific product. If it lists a regimen, ask which components are inside the quoted scope and which are not.
This is also where you confirm the biomarker context. Ask which report the hospital is relying on, whether it accepts the report you already have, and whether it wants the original pathology material or a repeat assessment. Do not assume that a biomarker result is actionable for every drug, or that a finding automatically points to one treatment. That judgement belongs to the treating clinicians, and it is exactly the judgement the quote should reflect.
Compare the monitoring and support lines, not just the infusion
Targeted therapy is not a single event. It usually involves assessment before starting, monitoring during treatment, and a plan for how the patient will be reviewed if something changes. Two quotes can look similar at the drug line and differ sharply once monitoring is included.
Ask what the quoted scope covers for laboratory work, imaging, clinic reviews, and any supportive medicines. Ask how many review visits the figure assumes, and what happens to the quote if the plan changes after the first assessment. You are not trying to predict every change; you are trying to learn whether the number is a fixed package or an estimate that will move.
A useful question is: what would make this quote change? Hospitals that answer clearly are giving you something more valuable than a low total, because you can see the assumptions. If a reply says the figure is provisional pending assessment, that is not a problem in itself. The problem is a provisional figure presented as final.
Separate hospital charges from coordination and travel costs
A hospital quote covers hospital services. It does not automatically cover interpretation, appointment coordination, travel, accommodation, or the practical support around a visit. Those are separate, and mixing them into one comparison hides what you are actually paying for. The same applies to the drug itself: a figure that bundles the medicine, its administration and the surrounding visits into one line cannot be compared with a figure that lists them separately, because you cannot tell which component is driving the difference.
Ask each hospital what its written quote includes and excludes, and who the payee is for each part. Then keep your own simple table with three columns: hospital charges, coordination charges, and travel and living costs. Fill it in only with what a provider has confirmed in writing, and leave a cell blank rather than guessing. A blank cell is useful information: it tells you which question is still unanswered before you treat two totals as alternatives.
Pay attention to how each quote handles the drug supply line. Ask whether the quoted amount covers the medicine only, the medicine plus administration, or a broader package that also folds in reviews and laboratory work. If one hospital quotes a per-cycle figure and another quotes a figure for a fixed number of cycles, convert both to the same unit before comparing. If a reply will not separate these components, ask directly which part of the total is medicine and which part is service, and note the answer.
If you use a coordination service, ask how its fee relates to the hospital's charges and who the payee is for each part. Coordination fees and hospital medical fees are separate, and they are not credited, deducted or offset against each other. Treat any offer that blurs this as a reason to ask more questions, not less. A written breakdown from each side, kept side by side, is what makes the comparison honest.
One more distinction matters when the patient is already receiving treatment elsewhere. Ask each hospital whether its quote assumes the patient starts a new regimen or continues an existing one, because a continuation quote may exclude the initial assessment that a new-start quote includes. If the two hospitals are answering different questions, say so in your own notes and do not average the totals. The goal is a like-for-like scope, and where the scopes differ, the honest answer is that the figures are not yet comparable.
Ask how ongoing treatment and monitoring would continue
For a patient already on targeted therapy, the practical question is often continuity rather than the first cycle. Ask each hospital how it would handle ongoing treatment if you travel: what records it needs, how it would review progress, and how it would communicate with the team already treating the patient.
Ask what the hospital would need before it could confirm whether it can assess the case at all. A records-based review can help clinicians understand the situation, but it does not establish that the hospital will accept the patient, that a particular medicine is available, or that treatment can start on a chosen date. Those are separate confirmations, and each should be requested explicitly.
If medicine needs to cross a border with the patient, that is a customs and regulatory question, not a clinical one. Customs authorities decide what may enter, and the relevant pharmacy or provider handles dispensing and stock. Ask the hospital and the appropriate authority directly rather than relying on a general answer.
Put the comparison in writing and ask one closing question
Once replies arrive, send each hospital the same short follow-up: please confirm the exact drug and regimen, the biomarker report you are relying on, the period the quote covers, what is included and excluded, and what would change the figure. This single message turns vague totals into comparable scopes, and it gives you a written record if you later need to clarify anything.
Then ask the question that decides the comparison: on the basis of the records provided, can this hospital assess the case, and what would it need next? A clear answer here matters more than a lower number, because it tells you whether the quote describes care the hospital can actually plan.
If you want help organising records, requesting a specialist appointment, or interpreting replies, ChinaSpecialistCare can assist with non-clinical coordination. An initial enquiry is free and does not require buying a proxy consultation. The hospital and its clinicians decide suitability, treatment and availability.
For background on how targeted therapy is assessed and planned, see the related reference on targeted cancer therapy.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.